Skip to main content

Biopsy (NCT06639074)

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial: a one-minute explainerNCT066390741 min

Biopsy trial for Advanced Fallopian Tube Carcinoma (NCT06639074). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with selected stage three or four ovarian, fallopian-tube or primary peritoneal cancers, without remaining disease after surgery and one platinum-chemotherapy course. Pathogenic BRCA1 or BRCA2 mutations are excluded.

The idea: compare a personalized dendritic-cell vaccine with placebo. Collected white blood cells are prepared to teach immune recognition of folate receptor alpha. Injections go into the skin, initially every three weeks, then every thirteen weeks. Researchers test whether recurrence is delayed.

This phase 2 study plans 78 patients. Matthew Block leads three recruiting Mayo Clinic sites.

Public record; not medical advice.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.